N2,N4-bis(4-chlorophenyl)pyrimidine-2,4-diamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N2,N4-bis(4-chlorophenyl)pyrimidine-2,4-diamine
• 英文别名: 2-N,4-N-bis(4-chlorophenyl)pyrimidine-2,4-diamine
• 化学式: C₁₆H₁₂Cl₂N₄
• 分子量: 331.2
• InChiKey: BPMAQQLXSXAFLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Novel compositions and methods for treating hyperproliferative diseases
  申请人：Chen, Chien-Hung

  公开号：EP2123267A1

  公开（公告）日：2009-11-25

  The invention relates to a composition that includes a first agent selected including an agent that possesses anti-inflammatory activity or acetaminophen, phenacetin, tramadol and the like; a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5-monophosphate-activated Protein kinase (AMPK) activator; a third agent that possesses or maintains serotonin activity.

  本发明涉及一种组合物，其中包括第一种药剂，选自具有抗炎活性的药剂或对乙酰氨基酚、苯乙哌啶、曲马多等；第二种药剂，选自氧化磷酸化抑制剂、离子贮存剂和腺苷-5-单磷酸激活蛋白激酶（AMPK）激活剂；第三种药剂，具有或保持血清素活性。
• Novel composition for treating metabolic syndrome
  申请人：IPINTL, LLC

  公开号：EP2494967A1

  公开（公告）日：2012-09-05

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5'-monophosphate-activated Protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

  本发明涉及一种组合物，其中包括选自氧化磷酸化抑制剂、离子贮存剂和腺苷-5'-单磷酸激活的蛋白激酶（AMPK）激活剂组成的组的第一种药剂；具有抗炎活性的第二种药剂；以及具有血清素活性的第三种药剂。
• NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME
  申请人：IPINTL, LLC

  公开号：EP2118279B1

  公开（公告）日：2017-11-22
• TREATING ALZHEIMER'S DISEASE AND OSTEOPOROSIS AND REDUCING AGING
  申请人：IPINTL, LLC

  公开号：EP2408434A1

  公开（公告）日：2012-01-25
• Novel Compositions and Methods for Treating Hyperproliferative Diseases
  申请人：Chen Chien-Hung

  公开号：US20090286760A1

  公开（公告）日：2009-11-19

  The invention relates to a composition that includes a first agent selected including an agent that possesses anti-inflammatory activity or acetaminophen, phenacetin, tramadol and the like; a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5-monophosphate-activated Protein kinase (AMPK) activator; a third agent that possesses or maintains serotonin activity.